ADVA
2.6.2020 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Zenlayer is deploying its FSP 3000 technology to provide dynamic, highly available services to some of the world’s biggest gaming, cloud computing and social media companies. The solution will deliver flexible, ultra-low-latency connectivity, enabling the cloud service provider to address huge bandwidth needs as and when required. This is essential for Zenlayer’s customers that require highly resilient services with dynamic capacity. Built on the compact and scalable ADVA FSP 3000 platform , the new network will carry multiple services, including Ethernet, Fibre Channel and SONET/SDH. For maximum efficiency and elasticity, it also features ADVA’s QuadFlex™ line cards and OpenFabric™ cross-connect technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005062/en/
“With this deployment, we’re injecting new levels of flexibility and reliability into our infrastructure. ADVA’s technology offers a major boost to our customers who are delivering more and more data-intensive real-time services to their end users. It opens the door to the next generation of teleconferencing, streaming and online gaming technologies,” said Alex Wang, network architect and product manager, Zenlayer. “Our new solution is extremely efficient in terms of footprint and power consumption. It’s also a future-proof investment ready to scale even further in years to come. Another key component in the success of the project was our close working relationship with ADVA’s engineers. They made sure the whole process was seamless and speedy from network design to shipment and implementation.”
Zenlayer’s new transport network includes some of ADVA’s most innovative technology. Specifically designed for scale and bandwidth optimization, the ADVA FSP 3000 platform ensures that the infrastructure meets the most stringent density and energy demands. Using ADVA FSP 3000 QuadFlex™ technology, the solution delivers outstanding spectral efficiency. The new network also features the ADVA FSP 3000 OpenFabric™ , an OTN cross-connect that creates a distributed architecture, empowering Zenlayer to simply and efficiently adjust bandwidth and turn up new services in an instant. What’s more, for Zenlayer customers such as public cloud and global gaming companies, the solution’s low-latency, high-availability performance will translate directly into end-user satisfaction.
“This deployment will benefit a great number of enterprises operating in Taiwan and Singapore. With the ability to flexibly and efficiently transport multi-traffic services at speeds up to 200Gbit/s, Zenlayer’s telecom, cloud service and gaming customers can enhance the experience of their end users and gain a vital competitive edge,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Zenlayer has a clear vision of what its customers expect and a bold strategy for delivering it. By harnessing our technology and the expertise of our engineers, Zenlayer has created a network ready to adapt to evolving demands and able to expand further in years to come.”
“Our open FSP 3000 technology is the ultimate response to ever-increasing data requirements. It gives Zenlayer the tools it needs to grow its network and develop its edge cloud services in a cost-efficient and highly sustainable way,” said Rocky Weicong Zhou, director, global business development, ADVA. “Combined with our QuadFlex™ and OpenFabric™ technologies, our FSP 3000 platform provides superb levels of capacity and agility. It enables Zenlayer to respond flexibly to huge increases in traffic volume while at the same time making savings on energy use and rack space. With a highly flexible and efficient transport system, Zenlayer can give its enterprise customers world-class connectivity to markets across the globe.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005062/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 15:10:00 CET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release
Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release
Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
